Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) issued its earnings results on Tuesday. The company reported ($5.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($5.30), Bloomberg Earnings reports.

Deciphera Pharmaceuticals (NASDAQ:DCPH) traded down $0.16 during trading hours on Wednesday, reaching $17.51. The company had a trading volume of 131,200 shares, compared to its average volume of 219,764. Deciphera Pharmaceuticals has a one year low of $16.11 and a one year high of $24.50.

A number of research firms have recently commented on DCPH. Instinet began coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued a “buy” rating and a $57.00 price objective for the company. J P Morgan Chase & Co began coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They issued an “overweight” rating and a $30.00 target price on the stock. JMP Securities assumed coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They issued an “outperform” rating and a $38.00 target price on the stock. Nomura began coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They issued a “buy” rating and a $57.00 target price on the stock. Finally, Piper Jaffray Companies began coverage on shares of Deciphera Pharmaceuticals in a report on Monday, October 23rd. They set an “overweight” rating and a $35.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $43.40.

In other news, major shareholder New Leaf Venture Management Ii purchased 375,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were purchased at an average price of $17.00 per share, for a total transaction of $6,375,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/15/deciphera-pharmaceuticals-inc-dcph-posts-quarterly-earnings-results-misses-expectations-by-5-30-eps.html.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Receive News & Ratings for Deciphera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.